ArticleEuropean geriatric medicine2025
Comorbidities and comorbidity burden in patients with neurocognitive disorders: findings from the MEMORA Cohort Study.
Article in European geriatric medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Genetic evidence links hypertension to accelerated brain aging.Biogerontology · 2026Article
- A culturally tailored iSupport model for dementia carers: Study protocol for a hybrid type I randomised controlled trial.International journal of nursing studies advances · 2026Article
- From artery to memory: a comparative review of vascular cognitive impairment surgical models.Frontiers in aging neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to compare comorbidities' prevalence and the comorbidity burden as measured by comorbidity indices according to the stages and the etiological diagnoses of neurocognitive disorders (NCD). This study aimed also to examine how comorbidities and comorbidity indices were associated with both stages and etiologies of NCD.
methodsThis is a cross-sectional study including participants from the MEMORA real-life cohort, aged ≥ 60 years. Patients had to be in either MCI or dementia stage, with the following etiological diagnoses of NCD: AD, VD (vascular dementia), mixed dementia (MD), dementia with Lewy bodies, frontotemporal dementia and Parkinson's disease. Three comorbidity indices were used to measure comorbidity burden: the Charlson comorbidity index, the multimorbidity-weighted index (MWI) and the health-related quality of life comorbidity index (HRQOL-CI). Prevalence of comorbidities involved in the calculation of at least one comorbidity index were reported. The associations between comorbidities/comorbidity indices and groups were assessed using binary and multinomial logistic regressions.
resultsOverall, 3470 patients (66.9% dementia; 50.9% AD) were included. The most frequent comorbidities were hypertension (50.2%), depression (28.0%) and hypercholesterolemia (22.6%). The MWI and the HRQOL-CI were associated with increased odds of dementia (vs. MCI). Upon stratifying population according to the etiological diagnoses of NCD, the highest mean of the three comorbidity indices were found in patients with VD and MD.
conclusionComorbidities and comorbidity burden vary according to the stage and etiological diagnoses of NCD. Future studies should consider the stage and the etiological diagnoses, when studying the effect of the comorbidity burden on the progression of NCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.